Rosenblatt analyst Barton Crockett maintains Fox (NASDAQ:FOXA) with a Neutral and raises the price target from $31 to $35.
Pulmatrix Granted U.S. Patent Titled ‘Monovalent metal cation dry powders for inhalation’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6272&f=G&l=50&d=PTXT&p=126&S1=20211116&OS=20211116&RS=20211116